Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-04991532. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04991532 SCHEMBL29358476 | 1.00 | GCK (1.00) | GCKHCAR3 | |
| Pf-04991532 SCHEMBL1711504 | 1.00 | GCK (1.00) | GCKHCAR3 | |
| SCHEMBL1711699 | 0.99 | GCK (0.98) | GCKHCAR3 | |
| SCHEMBL1711703 | 0.99 | GCK (0.98) | GCKHCAR3 | |
| SCHEMBL1711931 | 0.92 | GCK (0.85) | GCK | |
| SCHEMBL2201105 | 0.92 | GCK (0.85) | GCK | |
| SCHEMBL1711891 | 0.92 | GCK (0.85) | GCK | |
| SCHEMBL1711894 | 0.92 | GCK (0.85) | GCK | |
| SCHEMBL1711954 | 0.90 | GCK (0.82) | GCK | |
| SCHEMBL1711955 | 0.90 | GCK (0.82) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | claimed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | claimed |
| EP-2344458-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | claimed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | claimed |
| US-20250313532-A1 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-10-09 | — | — | US | disclosed |
| WO-2023235753-A2 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20200188394-A1 | TREATMENT OF LIVER DISEASE | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2020-06-18 | — | — | US | disclosed |
| EP-3558375-A1 | TREATMENT OF LIVER DISEASE | University of Newcastle Upon Tyne (GB) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115845-A1 | TREATMENT OF LIVER DISEASE | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2018-06-28 | — | — | WO | disclosed |
| WO-2014112798-A1 | NOVEL PHENYLETHYNYL BENZAMIDE GLUCOKINASE ACTIVATOR AND METHOD FOR PREPARING SAME | 주식회사유한양행 (KR) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014112799-A1 | PHENOXYBENZAMIDE GLUCOKINASE ACTIVATOR CONTAINING NOVEL HETEROARYL AND METHOD FOR PREPARING SAME | 주식회사유한양행 (KR) | 2014-07-24 | — | — | WO | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | disclosed |
| EP-2344458-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313532-A1 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | ADH1A, ALDH1A1, ADH1C | GCK 1345/4885HCAR3 1737/4885 |
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885HCAR3 830/4885 |
| US-20110230445-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885HCAR3 809/4885 |
| US-20100063063-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885HCAR3 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.